Nurix Therapeutics, Inc.: dividend

NRIXNASDAQHealthcare · Pharmaceutical Preparations

Price

$15.48

November 13, 2026Market cap $1.7B

What Ploutos Investor adds for Nurix Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from FY2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 30% since Oct 13, 2026, when the 10-Q these figures come from was filed ($22.13 then, $15.48 on Nov 13, 2026). The figures date from before that move.10-Q
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Nurix Therapeutics pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 35.5% in a year.

All dividend stocks

The full analysis

What do Nurix Therapeutics's filings show?

The dividend is one part of Nurix Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NRIX's dividend

Didn't find what you were looking for?

Ask us
Does NRIX pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 35.5% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.